U.S. market Closed. Opens in 1 day 20 hours 38 minutes

KZR | Kezar Life Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 6.35 - 6.75
52 Week Range 5.20 - 11.40
Beta 0.56
Implied Volatility 156.17%
IV Rank 37.06%
Day's Volume 71,567
Average Volume 107,369
Shares Outstanding 7,296,220
Market Cap 46,549,884
Sector Healthcare
Industry Biotechnology
IPO Date 2018-06-21
Valuation
Profitability
Growth
Health
P/E Ratio -0.49
Forward P/E Ratio N/A
EPS -13.12
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 58
Country USA
Website KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
*Chart delayed
Analyzing fundamentals for KZR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see KZR Fundamentals page.

Watching at KZR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on KZR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙